Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTAU.L Regulatory News (TAU)

  • There is currently no data for TAU

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

2 Sep 2019 07:00

RNS Number : 7787K
Tau Capital PLC
02 September 2019
 

 

 

 

2 September 2019

TAU CAPITAL PLC

(the "Company" or "Tau")

Interim Results

Tau Capital Plc ("Tau" or the "Company"), today announces its interim results for the six months ended 30 June 2019.

For further information, please contact:

FIM Capital Limited

Philip Scales +44 (0) 1624 681250

 

Allenby Capital Limited (Nominated Adviser and Joint-Broker)

John Depasquale / Alex Brearley +44 203 328 5656

 

Peterhouse Corporate Finance Limited (Joint-Broker)

Lucy Williams / Eran Zucker +44 207 469 0933

 

Chairman's Statement

 

It is less than nine weeks since the Annual Financial Statements for the year ended 31 December 2018 were issued along with my last statement but, since then, your Board has continued to review a number of potential opportunities for a Reverse Takeover ("RTO"). The Board is very aware of the need to act quickly given that the admission to trading of the Company's ordinary shares on AIM will be cancelled if such a transaction is not completed by the relevant date in October 2019. The Board are considering a number of possibilities including applying for admission to a different exchange.

In the meantime, a close watch is being kept on all expenses and, wherever possible, cost savings will continue to be made.

As soon as there is material progress with an RTO, an appropriate announcement will be made.

 

Gerwyn Williams

Chairman

30 August 2019

 

 

Condensed Statement of Comprehensive Income

 

 

 

For the six months ended

30 June 2019

For the year ended 31 December 2018

For the six months ended

 30 June 2018

 

 

(Unaudited)

(Audited)

(Unaudited)

 

Note

US$

US$

US$

 

 

 

 

 

Investment income

 

 

 

 

Interest income

 

-

7

6

Net gain/(loss) on financial assets and liabilities at fair value through profit or loss

-

45,050

(6,244)

Total operating gain/(loss)

 

-

45,057

(6,238)

 

 

 

 

 

Expenses

 

 

 

 

Operating expenses

8

(200,757)

(502,667)

(204,688)

Loss for the period/year:

 

(200,757)

(502,667)

(210,926)

 

 

 

 

 

Total comprehensive loss for the period/year attributable to shareholders

 

(200,757)

(457,610)

(210,926)

 

 

 

 

 

 

 

 

 

 

Basic and diluted loss per share (cents)

11

(0.17)

(0.93)

(0.43)

 

 

All results derive from continuing operations.

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

Condensed Statement of Financial Position

 

 

 

 

 

 

Note

As at

30 June 2019

(Unaudited)

US$

As at

31 December 2018

(Audited)

US$

As at

30 June 2018

(Unaudited)

US$

 

 

 

 

 

Assets

 

 

 

 

Investments in subsidiaries

4

-

-

2,560,349

Cash

 

147,455

1,407,341

105,199

Debtors and prepayments

 

52,499

22,224

40,465

Loan to subsidiary

6

-

-

111,574

Total assets

 

199,954

1,429,565

2,817,587

 

 

 

 

 

Liabilities

 

 

 

 

Creditors and accruals

 

(70,383)

(63,808)

(78,699)

Loan from subsidiary

6

-

-

(1,126,447)

Total liabilities

 

(70,383)

(63,808)

(1,205,146)

 

 

 

 

 

Total net assets

129,571

1,365,757

1,612,441

 

 

 

 

 

Shareholders' equity

 

 

 

 

Share capital

5

1,126,209

976,209

976,209

Distributable reserves

 

(996,638)

389,548

636,232

Total shareholders' equity

 

129,571

1,365,757

1,612,441

 

 

 

 

 

Net Asset Value per share (cents)

 

0.26

2.79

3.29

 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

Approved by the Board of Directors and signed on its behalf by:

 

Gerwyn Williams Philip Scales

 

30 August 2019

 

Condensed Statement of Changes in Equity for the

six months ended 30 June 2019

 

Share

Distributable

Total

 

capital

reserves

 

 

(Unaudited)

(Unaudited)

 (Unaudited)

 

US$

US$

 US$

Balance at 31 December 2018

976,209

389,548

1,365,757

Loss for the period

-

(200,757)

(200,757)

Total comprehensive loss for the period

-

(200,757)

(200,757)

Transactions with shareholders

 

 

 

Redenomination of ordinary shares to no par value

(976,209)

976,209

-

Distribution to ordinary shareholders

-

(1,185,429)

(1,185,429)

Placing of ordinary shares

-

150,000

150,000

Total transactions with ordinary shareholders

(976,209)

(59,220)

(1,035,429)

Balance at 30 June 2019

-

129,571

129,571

 

 

 

 

 

 

Condensed Statement of Changes in Equity for the

year ended 31 December 2018

 

Share

Distributable

Total

 

capital

reserves

 

 

(Audited)

(Audited)

(Audited)

 

US$

US$

 US$

Balance at 31 December 2017

976,209

847,158

1,823,367

Total comprehensive loss for the year

-

(457,610)

(457,610)

Balance at 31 December 2018

976,209

389,548

1,365,757

 

 

 

 

 

Condensed Statement of Changes in Equity for the

six months ended 30 June 2018

 

Share

Distributable

Total

 

capital

reserves

 

 

(Unaudited)

(Unaudited)

 (Unaudited)

 

US$

US$

 US$

Balance at 31 December 2017

976,209

847,158

1,823,367

Total comprehensive loss for the period

-

(210,926)

(210,926)

Balance at 30 June 2018

976,209

636,232

1,612,441

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

Condensed Statement of Cash Flows for the

six months ended 30 June 2019

 

For the six months

 For the year ended

For the six months

 

ended 30 June 2019

31 December 2018

ended 30 June 2018

 

(Unaudited)

(Audited)

(Unaudited)

 

US$

US$

US$

Cash flows from operating activities

 

 

 

Loss for the period/year

(200,757)

(457,610)

(210,926)

Adjustments to reconcile loss for the period/year to net cash provided by operating activities:

 

 

 

Net (gain)/loss on financial assets at fair value through profit or loss

-

(45,050)

6,244

Working capital adjustments:

 

 

 

Increase in debtors and prepayments

(30,274)

(7,081)

(25,322)

Decrease/(increase) in creditors and accruals

6,575

(26,325)

(11,434)

 

(224,457)

(536,066)

(241,438)

 

 

 

 

Proceeds from the disposal of Stopharm

-

1,202,512

-

Receipts of payments from subsidiaries

-

671,111

276,853

Net cash from operating activities

-

1,337,557

276,853

Cash flows from financing activities

 

 

 

Distributions paid to holders of ordinary shares

(1,185,429)

-

-

Proceeds from the issue of ordinary shares

150,000

-

-

Net cash from financing activities

(1,035,429)

-

-

 

 

 

 

Net (decrease)/increase in cash and cash equivalents

(1,259,886)

1,337,557

35,415

 

 

 

 

Cash and cash equivalents at the beginning of period/year

1,407,341

69,784

69,784

 

 

 

 

Cash and cash equivalents at the end of period/year

147,455

1,407,341

105,199

 

 

 

 

 

The accompanying notes are an integral part of these condensed financial statements.

 

 

Notes to the Condensed Financial Statements

 

1. General

 

Tau Capital Plc (the "Company") is a closed-ended investment company domiciled in the Isle of Man since 3 April 2007. The Company was incorporated under the Isle of Man Companies Acts 1931-2004. Following approval at the Annual General Meeting held on 24 July 2012, the Company was re-registered under the Isle of Man Companies Act 2006 with registered number 008604V. The Company's ordinary shares are admitted to trading on AIM, a market of that name operated by the London Stock Exchange. The Company has no employees.

 

On 18 October 2018, the Company completed the disposal of the Company's indirect interest in Stopharm LLP ("Stopharm") (see note 4). Following this disposal, under AIM Rule 15, the Company was then classified as a cash shell. The result of this was that the Company was required, within six months to make an acquisition which constitutes a reverse takeover under AIM Rule 14 or be re-admitted to trading on AIM as an investing company, failing which the Company's ordinary shares would be suspended. The Company's ordinary shares were suspended on 23 April 2019 and the Company now has up to six months from the date of suspension of the Company's ordinary shares to complete a reverse takeover or be readmitted to trading on AIM as an investing company or the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41.

 

The Company's subsidiaries, Tau (Cayman) L.P., Tau Cayman Limited and Tau SPV 1 Cooperatief WA ("Tau SPV 1") were dissolved on 20 December 2018, 31 January 2019 and 3 January 2019 respectively.

 

On 9 April 2019 the Company allotted and admitted to AIM 150,000,000 ordinary shares with one voting right each, raising gross proceeds of US$150,000, via a placing.

 

On 12 April 2019 the Company made a distribution of US$1,185,429, equivalent to US$0.0242 per share to ordinary shareholders on record at 5 April 2019.

 

2. Statement of compliance

 

These interim financial statements have been prepared in accordance with IAS 34 Interim Financial Reporting. They do not include all of the information required for full annual financial statements, and should be read in conjunction with the financial statements of the Company as at the year ended 31 December 2018. The financial statements of the Company as at and for the year ended 31 December 2018 are available upon request from the Company's registered office at IOMA House, Hope Street, Douglas, Isle of Man IM1 1AP or at www.taucapitalplc.com.

 

This is the first set of financial statements in which IFRS 16 Leases has been applied. The Company is neither a lease or lessor, therefore the application has resulted in no measurement or disclosure impact on the financial statements.

 

A number of other new standards are effective from 1 January 2019 but they do not have a material effect on the financial statements.

 

3. Significant accounting Policies

 

The accounting policies applied in these interim financial statements are the same as those applied in the Company's financial statements as at 31 December 2018 other than noted above. There are no IFRS or IFRIC interpretations that are not yet effective that would be expected to have a material impact on the Company.

 

 

 

Key sources of estimation uncertainty

 

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates and assumptions. It also requires the Board of Directors to exercise its judgement in the process of applying the Company's accounting policies. Key estimates, assumptions and judgements that have significant risk of causing material adjustment to the carrying amount of assets and liabilities within the next financial period are outlined below.

 

Going concern

 

Following the liquidation of all subsidiaries and the suspension of trading of the Company's ordinary shares on the AIM as detailed in note 1, the Board has made an assessment of the Company's going concern. In light of this, the financial statements have been presented on a non-going concern basis, which assumes that the Company will be placed into liquidation, following the delisting of the Company's ordinary shares, should a reverse takeover not be completed or be readmitted to trading on AIM as an investing company by the relevant date in October 2019.

 

a) Segment reporting

 

IFRS 8 requires operating segments to be identified on the basis of internal reports about components of the Company that are regularly reviewed by the Board of Directors in order to allocate resources to the segment and assess its performance. The Directors are of the opinion that over the financial period, the Company held no operating segments.

 

4. Investments in Subsidiaries

 

At 30 June 2019 the Company held no subsidiaries. The fair value of Tau Cayman Ltd at 31 December 2018 was US$ nil and at 30 June 2018 was US$2,560,349.

 

From 1 January 2018 the Company classified its investments in subsidiaries in accordance with IFRS 9 Financial Instruments: Recognition and Measurement ("IFRS 9"). This standard replaces IAS 39 Financial Instruments: Recognition and Measurement ("IAS 39").

 

The Company valued its investments in subsidiaries in accordance with IFRS 13 - Fair Value Measurements ("IFRS 13"). IFRS 13 defines fair value and establishes a framework for measuring fair value.

 

Financial instruments included in each category are as follows:

 

Level 1 - Quoted market price

Level 2 - Market observable inputs

Level 3 - Non-market observable inputs

 

No financial assets were held at 30 June 2019 or 31 December 2018. At 30 June 2018 Level 3 financial assets of US$2,560,349 were held by the Company.

 

The following is a reconciliation of the movement in financial assets for which non-market observable inputs Level 3 were used to determine fair value in the comparative periods:

 

 

31 Dec 2018

30 June 2018

 

US$

US$

Opening balance at beginning of year/period

2,566,593

2,566,593

Opening loan balances netted off investments

(738,020)

-

Net loans and investments

1,828,573

2,566,593

 

 

 

Payments received from subsidiaries

(671,111)

-

Proceeds from the disposal of Stopharm

(1,202,512)

-

Net gain/(loss) on financial assets at fair value through profit or loss

45,050

(6,244)

 

(1,828,573)

2,560,349

Closing balance at end of year/period

-

2,560,349

 

There were no transfers between Levels during any of the reported financial period. Net realised and unrealised gains/(losses) on investments are recognised as investment income in the Condensed Statement of Comprehensive Income.

 

As at 30 June 2019 and 31 December 2018 the Company held no Level 3 financial assets. The only Level 3 financial asset measured at fair value at 30 June 2018 was the Company's investment in Tau Cayman L.P. which had a fair value of US$2,560,349. The investment was valued using a net realisable assets approach; details of the significant unobservable inputs in the valuation at 30 June 2018 included the perceived valuation of the Stopharm investment.

 

Fair value of the Company's Level 3 financial assets and financial liabilities that are measured at fair value on a recurring basis

 

Tau (Cayman) L.P.

Tau (Cayman) L.P. was dissolved on 20 December 2018, the assets and liabilities at 30 June 2018 were as follows:

 

 

As at 30 June 2018

 

US$

Cash

470,106

Debtors and prepayments

7,951

Investment in subsidiary

1,088,416

Loan to parent

1,131,620

Total assets

2,698,093

 

 

Accounts payable and accrued expenses

(12,560)

Loan from parent

(125,184)

Total liabilities

(137,744)

Total net assets

2,560,349

 

Tau SPV 1

Tau SPV 1 was dissolved on 31 January 2019. In the comparative periods the fair value of Tau SPV 1 was based on its net assets, which were as follows:

 

As at

31 December 2018

As at

30 June 2018

 

US$

US$

Cash

-

764

Financial assets at fair value through profit or loss

-

1,100,000

Total assets

-

1,100,764

 

 

 

Accounts payable and accrued expenses

-

(12,348)

Total liabilities

-

(12,348)

Total net assets

-

1,088,416

 

Stopharm

 

Stopharm is a wholesale pharmaceuticals distributor operating in Kazakhstan of which Tau SPV1 held 40.35 per cent of the equity. On 18 October 2018 the Company completed the disposal of the Company's indirect interest in Stopharm. The investment was valued at 30 June 2018 at US$1,100,000 based on estimated net proceeds at the date the accounts were signed.

 

5. Share Capital and Share Premium

 

The authorised share capital of the Company is £3,502,000 comprising 350,200,000 ordinary shares of no par value. The share capital of the Company has been allocated, called up and fully paid.

 

On 9 April 2019, the Company issued 150,000,000 ordinary shares with one voting right each. The number of shares in issue as at 30 June 2019 was 198,984,680 ordinary shares.

 

 

 

 

6. Intercompany loan

 

All of the Company's subsidiaries had been dissolved by 30 June 2019. In the comparative periods the loan balances were as follows:

 

31 December 2018

30 June 2018

 

US$

US$

Due to the Company - Tau SPV 1

-

111,574

Due from the Company - Tau (Cayman) L.P.

-

(1,126,447)

 

All the loans detailed above were interest free, unsecured and repayable on demand.

 

7. Related Party Items

 

Philip Scales, a Director of the Company is a director of FIM Capital Limited, the Company's Administrator.

 

On 12 April 2019, Gerwyn Williams was appointed as a Director. As at 30 June 2019, Gerwyn Williams held 32,530,000 ordinary shares in the Company.

 

On 12 April 2019, Nigel Burton was appointed as a Director. As at 30 June 2019, Nigel Burton held 26,024,000 ordinary shares in the Company.

 

On 12 April 2019, Philip Lambert resigned as a Director. As at 30 June 2019, Philip Lambert held 101,201 ordinary shares in the Company (101,201 shares at 30 June 2018 and 31 December 2018).

 

On 12 April 2019, Terence Mahony resigned as a Director. As at 30 June 2019, 30 June 2018 and 31 December 2018 Terence Mahony held 102,424 ordinary shares in the Company (102,424 shares at 30 June 2018 and 31 December 2018).

 

As at 30 June 2019, Richard Horlick, a previous Director of the Company held 12,684,221 ordinary shares (12,684,221 shares at 31 December 2018 and 30 June 2018). Global Asset Tracking, a company to whom Richard Horlick provides consultancy services, received no fees during the financial period (31 December 2018: GBP £48,000; 30 June 2018: GBP £48,000).

 

8. Operating expenses

 

Directors' remuneration

 

On 12 April 2019, both Philip Lambert and Terence Mahony resigned as Directors and Gerwyn Williams and Nigel Burton were appointed to the Board. Gerwyn Williams was also appointed Chairman. Gerwyn Williams and Nigel Burton do not receive a Directors' fee. From 12 April 2019 Philip Scales no longer receives a Directors' fee.

 

Included within operating expenses are the Directors' remunerations, which are shown below:

 

 

30 June 2019

31 Dec 2018

30 June 2018

 

US$

US$

US$

Philip Lambert

16,313

39,744

20,405

Terence Mahony

10,875

26,892

14,000

Philip Scales

3,910

15,864

8,162

Total Directors' remuneration

31,098

82,500

42,567

 

 

During the period ended 30 June 2019, none of the Directors received any additional cash or non-cash benefits (31 December 2018: US$nil; 30 June 2018: US$nil).

 

Administrator fees

 

The Administrator is entitled to receive a fixed fee of £35,000 for provision of administration services and US$35,000 for provision of accounting services per annum, payable quarterly in arrears. The Administrator's fees for the period ended 30 June 2019 amounted to US$45,075 (31 December 2018: US$91,154; 30 June 2018: US$46,369).

 

 

9. Exchange rates

 

The following exchange rates were used to translate assets and liabilities into US dollars:

 

As at 30 June 2019

As at 31 December 2018

As at 30 June 2018

 

Euro

1.11655

1.1467

1.16840

Pound sterling

1.26965

1.2754

1.32070

 

10. Distributions

 

On 5 April 2019 a distribution was declared of US$0.0242 per share, equivalent to US$1,185,429. The distribution was paid on 12 April 2019. No distributions or dividends were declared or paid during the year ended 31 December 2018 and 30 June 2018.

 

11. Loss per Share

 

Basic and diluted loss per share is calculated by dividing the net profit or loss attributable to shareholders by the weighted average number of ordinary shares outstanding during the period/year.

 

 

For the six months ended 30 June 2019

For the year ended 31 December 2018

For the six months ended 30 June 2018

Net loss attributable to shareholders

(US$200,757)

(US$457,610)

(US$235,402)

Weighted average number of ordinary shares in issue

117,318,013

48,984,680

48,984,680

Basic loss per share (cents)

(0.17)

(0.93)

(0.43)

 

There is no difference between the fully diluted earnings per share and basic earnings per share.

 

12. Subsequent events

 

Save as disclosed in this report, there were no events occurring after the date of the Condensed Statement of Financial Position that would have a material impact on this interim report.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IR PMMATMBIJBML
Date   Source Headline
1st Apr 200911:13 amRNSFinal Results
25th Mar 20092:45 pmRNSJoint Venture Investment
18th Mar 20091:52 pmRNSDirectorate Change
9th Mar 20099:26 amRNSNet Asset Value(s)
9th Feb 20094:03 pmRNSNet Asset Value(s)
27th Jan 20093:38 pmRNSHolding(s) in Company
27th Jan 20093:36 pmRNSHolding(s) in Company
21st Jan 20094:39 pmRNSHolding(s) in Company
20th Jan 200911:26 amRNSHolding(s) in Company
20th Jan 200910:37 amRNSDirector/PDMR Shareholding
9th Jan 20095:14 pmRNSNet Asset Value(s)
10th Dec 200812:07 pmRNSPrivate Equity Investment
8th Dec 20084:53 pmRNSHolding(s) in Company
8th Dec 20083:17 pmRNSNet Asset Value(s)
10th Nov 20084:03 pmRNSNet Asset Value(s)
28th Oct 20083:23 pmRNSPrivate Equity Investment
8th Oct 200811:14 amRNSNet Asset Value(s)
24th Sep 200811:43 amRNSPosting of Interims
12th Sep 20087:00 amRNSInterim Results
8th Sep 200811:06 amRNSNet Asset Value(s)
3rd Sep 200812:55 pmRNSResult of AGM
22nd Aug 20084:16 pmRNSHolding(s) in Company
8th Aug 20083:43 pmRNSNotice of AGM
8th Aug 20083:15 pmRNSNet Asset Value(s)
31st Jul 200810:10 amRNSTrading Statement
16th Jul 20084:38 pmRNSAppointment of Auditors
15th Jul 20087:00 amRNSTeam additions to investment
8th Jul 20083:22 pmRNSNet Asset Value(s)
20th Jun 20082:12 pmRNSTransaction in Own Shares
9th Jun 20084:17 pmRNSNet Asset Value(s)
8th Apr 20089:40 amRNSNet Asset Value(s)
28th Mar 200812:30 pmRNSAnnual Report and Accounts
25th Mar 20087:01 amRNSPreliminary Final Results
7th Mar 20084:47 pmRNSNet Asset Value(s)
7th Feb 200811:31 amRNSNet Asset Value(s)
31st Jan 200812:05 pmRNSTrading Update
23rd Jan 200811:19 amRNSHolding(s) in Company
21st Jan 200811:34 amRNSHolding(s) in Company
9th Jan 20082:50 pmRNSNet Asset Value(s)
10th Dec 20073:24 pmRNSNet Asset Value(s)
7th Nov 20072:58 pmRNSNet Asset Value(s)
5th Oct 20073:04 pmRNSNet Asset Value(s)
7th Sep 200711:22 amRNSNet Asset Value(s)
20th Aug 20077:02 amRNSAIM Notice (Rule 26)
8th Aug 20077:00 amRNSNet Asset Value(s)
11th Jul 20074:34 pmRNSHolding(s) in Company
9th Jul 20077:00 amRNSTrading Update
12th Jun 20072:39 pmRNSHolding(s) in Company
5th Jun 20074:53 pmRNSTrading Update
29th May 20079:50 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.